A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Canakinumab (Primary)
  • Indications Atherosclerosis; Cardiovascular disorders; Myocardial infarction
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CANTOS; CANTOS sub-study 1; CANTOS sub-study 2
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 19 Sep 2017 Results from the study published in a Cardax Pharmaceuticals media release.
    • 27 Aug 2017 The last trial visit of he pivotal phase (main study) was in June 2017, according to the results published in the New England Journal of Medicine
    • 27 Aug 2017 Results published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top